65.81
Cg Oncology Inc stock is traded at $65.81, with a volume of 755.03K.
It is up +3.09% in the last 24 hours and up +15.48% over the past month.
CG Oncology Inc is a late-stage clinical biopharmaceutical company focused on developing and commercializing its product candidate, cretostimogene grenadenorepvec, for patients with bladder cancer. The company's candidate, cretostimogene grenadenorepvec, is a targeted oncolytic intravesically delivered immunotherapy agent that is in two phase three trials (one high-risk BCG unresponsive NMIBC trial and one intermediate-risk NMIBC trial) and a phase two clinical study with a checkpoint inhibitor for high-risk BCG unresponsive NMIBC disease.
See More
Previous Close:
$63.84
Open:
$64.67
24h Volume:
755.03K
Relative Volume:
0.58
Market Cap:
$5.56B
Revenue:
$4.04M
Net Income/Loss:
$-161.00M
P/E Ratio:
-31.60
EPS:
-2.0823
Net Cash Flow:
$-132.48M
1W Performance:
+2.11%
1M Performance:
+15.48%
6M Performance:
+80.40%
1Y Performance:
+138.96%
Cg Oncology Inc Stock (CGON) Company Profile
Name
Cg Oncology Inc
Sector
Industry
Phone
(949) 419-6203
Address
400 SPECTRUM CENTER DRIVE, IRVINE
Compare CGON vs VRTX, REGN, ALNY, ARGX, INSM
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
|
CGON
Cg Oncology Inc
|
65.81 | 5.39B | 4.04M | -161.00M | -132.48M | -2.0823 |
|
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 113.96B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 78.41B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 40.85B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ARGX
Argen X Se Adr
|
697.05 | 42.05B | 4.16B | 1.29B | 734.26M | 19.58 |
|
INSM
Insmed Inc
|
148.31 | 29.99B | 606.42M | -1.28B | -997.58M | -6.403 |
Cg Oncology Inc Stock (CGON) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-11-25 | Initiated | Wedbush | Outperform |
| Nov-24-25 | Initiated | Truist | Buy |
| Oct-08-25 | Initiated | Guggenheim | Buy |
| Aug-19-25 | Initiated | Piper Sandler | Overweight |
| Jul-10-25 | Resumed | Goldman | Buy |
| May-02-25 | Initiated | JP Morgan | Overweight |
| Apr-16-25 | Initiated | Scotiabank | Sector Perform |
| Jan-07-25 | Initiated | TD Cowen | Buy |
| Oct-24-24 | Initiated | UBS | Buy |
| Sep-23-24 | Initiated | RBC Capital Mkts | Outperform |
| Aug-28-24 | Initiated | ROTH MKM | Buy |
| Jun-28-24 | Initiated | BofA Securities | Buy |
| Feb-20-24 | Initiated | Cantor Fitzgerald | Overweight |
| Feb-20-24 | Initiated | Goldman | Neutral |
| Feb-20-24 | Initiated | Morgan Stanley | Overweight |
| Feb-14-24 | Initiated | H.C. Wainwright | Buy |
View All
Cg Oncology Inc Stock (CGON) Latest News
Non Muscle Invasive Bladder Cancer Pipeline Expands as 20+ Pharma Companies Progress Novel Therapies Toward Market Entry, Finds DelveInsight | CG Oncology, Janssen, Tyra Biosciences, UroGen Pharma - Barchart.com
CG Oncology, Inc. (NASDAQ:CGON) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
CG Oncology Soars 102% in a Year, but One Investor Just Disclosed a $58.5 Million Sale - AOL.com
This Biotech Stock Up 135% Just Faced a $44 Million Trim. Here's What Investors Should Know - AOL.com
Kynam Capital Cuts CG Oncology Holding: Q4 2025 Sale Details & ImpactNews and Statistics - IndexBox
This Biotech Stock Surged 135% but Just Saw a $44 Million Sell-Off. What Does This Mean for Investors? - Bitget
CGON Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Bank of America Securities Remains a Buy on CG Oncology, Inc. (CGON) - The Globe and Mail
CG Oncology (CGON) Expected to Announce Quarterly Earnings on Friday - MarketBeat
Quarterly Trades: Can CG Oncology Inc deliver consistent EPS growth2026 Key Highlights & Real-Time Price Movement Reports - baoquankhu1.vn
Why CG Oncology Stock Is Suddenly Losing Steam - TipRanks
CG Oncology, Inc. Hits New 52-Week High of $59.95 - Markets Mojo
Highs Report: What is the dividend yield of CG Oncology IncWeekly Trade Review & Expert Verified Movement Alerts - baoquankhu1.vn
Dividend Watch: Is CG Oncology Inc impacted by rising rates2026 Earnings Surprises & Community Trade Idea Sharing - baoquankhu1.vn
Will CG Oncology Inc outperform tech stocksEarnings Miss & Growth Oriented Trade Recommendations - baoquankhu1.vn
CG Oncology (NASDAQ:CGON) Director James Mulay Sells 1,964 Shares - MarketBeat
CG Oncology (NASDAQ: CGON) director sells 1,964 shares after option exercises - Stock Titan
Analysts Offer Insights on Healthcare Companies: Xenon (XENE), Protagonist Therapeutics (PTGX) and CG Oncology, Inc. (CGON) - The Globe and Mail
Analysts Are Bullish on Top Healthcare Stocks: Protagonist Therapeutics (PTGX), CG Oncology, Inc. (CGON) - The Globe and Mail
CG Oncology, Inc. $CGON Stake Increased by HighVista Strategies LLC - MarketBeat
Boothbay Fund Management LLC Has $3.81 Million Stock Holdings in CG Oncology, Inc. $CGON - MarketBeat
CG Oncology (NASDAQ:CGON) Reaches New 52-Week HighShould You Buy? - MarketBeat
ArrowMark Colorado Holdings LLC Has $10.36 Million Holdings in CG Oncology, Inc. $CGON - MarketBeat
How Investors May Respond To CG Oncology (CGON) Expanding ATM Offering To Advance Cretostimogene BLA Efforts - simplywall.st
CG Oncology stock hits all-time high at 63.9 USD By Investing.com - Investing.com Nigeria
Is CG Oncology (CGON) Pricing Reflect Its Recent 131% Surge And Cancer Breakthrough Hopes - Yahoo Finance
Wall Street Analysts Believe CG Oncology, Inc. (CGON) Could Rally 157.91%: Here's is How to Trade - MSN
Mangrove Partners IM LLC Increases Stock Position in CG Oncology, Inc. $CGON - MarketBeat
Form 4 CG Oncology Inc For: 14 March - Investing.com
Form 4 CG Oncology Inc For: 14 March By Investing.com - Investing.com Australia
CG Oncology (NASDAQ: CGON) CEO net exercises options and increases share stake - Stock Titan
Rosalind Advisors Inc. Grows Holdings in CG Oncology, Inc. $CGON - MarketBeat
Is It Too Late To Consider CG Oncology (CGON) After A 143% One Year Surge? - simplywall.st
CG Oncology stock rallies nearly 32% in a week: Here is why - MSN
CG Oncology stock hits all-time high at 63.9 USD - Investing.com India
CG Oncology (NASDAQ:CGON) Sees Unusually-High Trading VolumeStill a Buy? - MarketBeat
CG Oncology (CGON) Valuation Check After Strong Recent Share Price Momentum - simplywall.st
CG Oncology (NASDAQ:CGON) Sets New 52-Week HighHere's What Happened - MarketBeat
CG Oncology Conference: Credo Posts 75.5% CR in BOND-003, BLA Filing Targeted for 2026 - MarketBeat
JPMorgan Chase & Co. Has $9.18 Million Stock Holdings in CG Oncology, Inc. $CGON - MarketBeat
Replimune Stock Pre-Market (+16%): Sector Momentum Lifts Oncolytic Virus Peers - Trefis
Insider Trends: Is CG Oncology Inc exposed to currency risksJuly 2025 Trade Ideas & Capital Efficient Trade Techniques - baoquankhu1.vn
H.C. Wainwright Raises its Price Target on CG Oncology, Inc. (CGON) to $80 and Maintains a Buy Rating - Finviz
CG Oncology (CGON) CEO nets 100,000 shares from option exercise - Stock Titan
10 Fastest Growing NASDAQ Stocks to Buy - Insider Monkey
Rafferty Asset Management LLC Lowers Stock Position in CG Oncology, Inc. $CGON - MarketBeat
Tech Rally: Will CG Oncology Inc stock recover after earningsInsider Buying & Risk Managed Investment Strategies - baoquankhu1.vn
Stock Traders Buy High Volume of Call Options on CG Oncology (NASDAQ:CGON) - MarketBeat
CG Oncology, Inc. $CGON Stock Holdings Trimmed by TD Asset Management Inc - MarketBeat
Lifesci Capital Predicts Stronger Earnings for CG Oncology - MarketBeat
CG Oncology (NASDAQ:CGON) Sets New 12-Month HighTime to Buy? - MarketBeat
Cg Oncology Inc Stock (CGON) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):